Level Four Advisory Services LLC Buys 2,458 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Level Four Advisory Services LLC boosted its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 17.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,201 shares of the medical instruments supplier’s stock after acquiring an additional 2,458 shares during the quarter. Level Four Advisory Services LLC’s holdings in Merit Medical Systems were worth $1,567,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. NewSquare Capital LLC acquired a new stake in shares of Merit Medical Systems in the 4th quarter valued at about $32,000. Kohmann Bosshard Financial Services LLC bought a new stake in Merit Medical Systems in the 4th quarter valued at approximately $52,000. Smartleaf Asset Management LLC lifted its stake in Merit Medical Systems by 237.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier’s stock valued at $134,000 after acquiring an additional 977 shares in the last quarter. GAMMA Investing LLC boosted its position in Merit Medical Systems by 14.7% during the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier’s stock worth $144,000 after acquiring an additional 191 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in shares of Merit Medical Systems by 13.9% in the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock valued at $171,000 after purchasing an additional 211 shares during the last quarter. 99.66% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Merit Medical Systems

In related news, CFO Raul Jr. Parra sold 12,451 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $98.81, for a total value of $1,230,283.31. Following the completion of the sale, the chief financial officer now directly owns 24,201 shares in the company, valued at approximately $2,391,300.81. The trade was a 33.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Stephen C. Evans sold 5,000 shares of Merit Medical Systems stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total value of $526,550.00. Following the completion of the transaction, the director now directly owns 4,657 shares of the company’s stock, valued at $490,428.67. This represents a 51.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,132 shares of company stock worth $11,139,521. Insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Canaccord Genuity Group decreased their target price on shares of Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Raymond James raised their price objective on Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, December 31st. Barrington Research dropped their target price on Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. JPMorgan Chase & Co. started coverage on Merit Medical Systems in a research note on Friday. They issued an “overweight” rating and a $120.00 price target for the company. Finally, Wells Fargo & Company dropped their price objective on Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $111.70.

Merit Medical Systems Price Performance

NASDAQ:MMSI opened at $103.94 on Friday. The company has a market cap of $6.12 billion, a P/E ratio of 50.95, a P/E/G ratio of 2.34 and a beta of 0.91. The firm’s fifty day moving average price is $104.30 and its two-hundred day moving average price is $101.03. Merit Medical Systems, Inc. has a one year low of $70.70 and a one year high of $111.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.